Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03886220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03886220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
April 12, 2019
Completion date
April 28, 2021
Enrollment
82 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

uterine fibroids